Catalyst Dossier · compiled by CeliA 🧫
Galecto, Inc. (GLTO)
Pharmaceutical Preparations · market cap $38M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Galecto, Inc. (GLTO) is a small-cap pharmaceutical company with a market cap of approximately $38M and a share price near $28.91, developing a pipeline of four assets across Phase 2 trials in NSCLC, myelofibrosis, and idiopathic pulmonary fibrosis (IPF). The company carries no analyst coverage, no disclosed cash runway, and no near-term catalysts on the calendar. Annual net losses have ranged from $21M to $62M over the past five years, with R&D spend declining sharply from a 2022 peak.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GB1211 | Phase 2 | Non-Small Cell Lung Cancer |
| GB2064 | Phase 2 | Myelofibrosis |
| GB0139 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) |
| Inhaled TD139 | Phase 2 | Idiopathic Pulmonary Fibrosis |
Price & technical context
3-month
+30.6%
6-month
+863.7%
12-month
+567.7%
52-wk range
$2.22–$34.14
vs 50-day MA
+9.4%
vs 200-day MA
+124.6%
Realized vol
245.3%
Max drawdown
-90.0%
Daily closes through 2026-03-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GLTO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.